Medtronic's new drug-eluting stent, Endeavor, is expected to help triple the company's sales over the next five years after its U.S. launch in 2007, the head of the company's vascular business said. Analysts see difficulties if the company can't gain the rights to license a technique called "rapid exchange," which facilitates stent delivery into the body, but the company said it expects strong growth regardless of rights to rapid exchange.

Full Story:

Related Summaries